What is the recommended proton pump inhibitor (PPI) dosing and duration for a 13-year-old child with gastro‑esophageal reflux disease, including erosive esophagitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

PPI Treatment for a 13-Year-Old with GERD

For a 13-year-old with gastroesophageal reflux disease, including erosive esophagitis, prescribe a proton pump inhibitor at weight-based dosing: omeprazole 0.7-3.3 mg/kg/day, lansoprazole 0.7-3.0 mg/kg/day, or esomeprazole 0.7-3.3 mg/kg/day, OR use rabeprazole 20 mg daily, which is FDA-approved for ages 12-17 years. 1

Medication Selection & Dosing

At 13 years old, this patient falls within the FDA-approved age range for multiple PPIs. Your options include:

FDA-Approved PPIs for This Age Group:

  • Rabeprazole: 20 mg daily (oral tablet) - FDA approved for ages 12-17 years 1
  • Omeprazole: 0.7-3.3 mg/kg/day - FDA approved ages 2-16 years (sprinkle capsule contents onto soft foods) 1
  • Lansoprazole: 0.7-3.0 mg/kg/day - FDA approved ages 1-17 years (multiple formulations including disintegrating tablets) 1
  • Esomeprazole: 0.7-3.3 mg/kg/day - FDA approved ages 1-17 years (sprinkle capsule contents) 1

Rabeprazole offers the simplest dosing (fixed 20 mg daily) for adolescents and is specifically FDA-approved for this age range. 1 For weight-based PPIs, the effective dosage range is fairly wide, with healing dose correlating with severity of esophagitis rather than age. 1

Key Clinical Evidence

PPIs are superior to H2-receptor antagonists for both symptom relief and healing rates of erosive esophagitis in children. 1 Studies demonstrate that lansoprazole at 0.7-3.0 mg/kg daily healed all cases of erosive esophagitis in children aged 1-12 years with GERD. 1 PPIs are considered safe and generally well-tolerated with relatively few adverse effects in children. 1

Dosing Timing & Administration

Administer PPIs approximately 30 minutes before meals for optimal efficacy, as effectiveness is directly related to timing of dosing. 2 The metabolism of PPIs differs in children compared to adults, requiring weight-adjusted dosing. 1

Duration & Monitoring Strategy

Use time-limited trials rather than indefinite therapy. 3 The guidelines emphasize that GERD is not chronic and relapsing in all children, even those with proven reflux esophagitis, thus trials of therapy withdrawal are warranted. 3

Recommended Approach:

  1. Initiate PPI therapy at appropriate weight-based dose
  2. Treat for 8-12 weeks for erosive esophagitis healing
  3. Reassess symptoms and consider step-down therapy
  4. Attempt planned discontinuation or dose reduction after symptom control achieved

Important Safety Considerations

Common pitfalls to avoid:

  • Do NOT prescribe indefinitely without reassessment - The dramatic increase in PPI prescriptions for pediatric patients raises concerns about overprescription 1, 4
  • Monitor for adverse effects: Headaches, diarrhea, constipation, and nausea occur in up to 14% of older children 1
  • Be aware of infection risks: Acid suppression with PPIs may increase risk of community-acquired pneumonia, gastroenteritis, and candidemia 1
  • Long-term concerns: Enterochromaffin cell hyperplasia has been demonstrated in up to 50% of children receiving PPIs for more than 2.5 years 1

Alternative Considerations

If PPI therapy fails or is not tolerated, H2-receptor antagonists remain an option, though they are less effective:

  • Ranitidine: 5-10 mg/kg/day divided in 2-3 doses (FDA approved 1 month-16 years) 1
  • Famotidine: 1 mg/kg/day divided in 2 doses (FDA approved 1-16 years) 1
  • Nizatidine: 10 mg/kg/day divided in 2 doses (FDA approved ≥12 years) 1

However, H2RAs develop tachyphylaxis within 6 weeks, limiting long-term effectiveness. 1

Adjunctive Non-Pharmacologic Measures

While initiating PPI therapy, recommend:

  • Weight loss if overweight
  • Avoiding trigger foods
  • Elevating head of bed
  • Avoiding late-night meals
  • Not smoking or using alcohol 2

References

4
Research

Proton pump inhibitors in children: indications and safety.

Expert review of gastroenterology & hepatology, 2026

Related Questions

Which proton pump inhibitors (PPIs) are recommended for children with gastro‑esophageal reflux disease, and what are the appropriate dosing regimens?
Can a 10-year-old take a Proton Pump Inhibitor (PPI)?
In a patient with erosive esophagitis who is already on an optimally timed proton‑pump inhibitor but continues to have nocturnal heartburn, should a prokinetic such as metoclopramide (or domperidone) be added, and what short‑term regimen is recommended?
What is the appropriate management of erosive esophagitis and dyspepsia in a patient who declines proton‑pump inhibitor therapy?
What is the appropriate dose of a proton‑pump inhibitor for a 10‑year‑old child with dyspepsia?
What is the optimal combination therapy for an adult with hair‑dye‑induced hyperpigmentation and no contraindications (e.g., no melasma, active dermatitis, pregnancy, or hypersensitivity)?
What is the recommended dosing schedule for Junel Fe (norgestimate/ethinyl estradiol with iron)?
In a 55-year-old man with newly diagnosed type 2 diabetes mellitus on metformin 1000 mg twice daily and a sulfonylurea (gliclazide or glyburide) for six months, with mildly elevated fasting plasma glucose and HbA1c within target, what is the appropriate next step in management?
What medication would be the best option for this patient?
Does an elevated bilirubin level indicate the presence or formation of gallbladder stones?
What dosage strengths are available for Junel Fe (norgestimate/ethinyl estradiol with ferrous fumarate)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.